BML Capital Urges ESSA Pharma (NASDAQ: EPIX) to Pursue Liquidation or Cash Return Amid Market Challenges
Summary
April 24, 2025
Board of Directors
ESSA Pharma Inc.
999 West Broadway
Vancouver, British Columbia
Canada V5Z iK5
c/o Dr. David R. Parkinson, President and CEO
Dear Directors:
I am writing on behalf of BML Capital Management, LLC and BML Investment Partners L.P. (collectively BML), a holder of 9.5% of the outstanding shares of ESSA Pharma, Inc.
BML agrees with recent public suggestions by other large shareholders that a return of the company’s capital to shareholders via liquidation is a sensible course of action in today’s difficult market conditions. As such, BML would be supportive of such an action, or, in the absence of this, a similar transaction that would quickly return the majority of the company’s cash to shareholders, such as a sale of the company or a large special dividend.
Regards,
Braden M Leonard
Managing Member
BML Capital Management, LLC
Source:
https://www.sec.gov/Archives/edgar/data/1373604/000137360425000063/bmlletter.htm
Member discussion